Frank Padberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frank Padberg has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
D Keeser
5 shared publications- Ulrich Palm
Department of Psychiatry and Psychotherapy, Klinikum der Universität München, Munich, Germany
5 shared publications A. Hasan
Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München
4 shared publications- Daniel Keeser
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich
4 shared publications O Pogarell
4 shared publicationsO. Pogarell
Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München
4 shared publications
Latest Publications
- Open Access
- 22 October 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 273 (1) , 85-98
Examining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol
Enhanced behavioral interventions are gaining increasing interest as innovative treatment strategies for major depressive disorder (MDD). In this study protocol, we propose to examine the synergistic effects of a self-administered home-treatment, encompassing transcranial direct current stimulation (tDCS) along with a video game based training of attentional control. The study is designed as a two-arm, double-blind, randomized and placebo-controlled multi-center trial (ClinicalTrials.gov: NCT04953208). At three study sites (Israel, Latvia, and Germany), 114 patients with a primary diagnosis of MDD undergo 6 weeks of intervention (30 × 30 min sessions). Patients assigned to the intervention group receive active tDCS (anode F3 and cathode F4; 2 mA intensity) and an action-like video game, while those assigned to the control group receive sham tDCS along with a control video game. An electrode-positioning algorithm is used to standardize tDCS electrode positioning. Participants perform their designated treatment at the clinical center (sessions 1–5) and continue treatment at home under remote supervision (sessions 6–30). The endpoints are feasibility (primary) and safety, treatment efficacy (secondary, i.e., change of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at week six from baseline, clinical response and remission, measures of social, occupational, and psychological functioning, quality of life, and cognitive control (tertiary). Demonstrating the feasibility, safety, and efficacy of this novel combined intervention could expand the range of available treatments for MDD to neuromodulation enhanced interventions providing cost-effective, easily accessible, and low-risk treatment options.ClinicalTrials.gov: NCT04953208.
- 22 October 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 273 (1) , 85-98
Open AccessExamining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol
Enhanced behavioral interventions are gaining increasing interest as innovative treatment strategies for major depressive disorder (MDD). In this study protocol, we propose to examine the synergistic effects of a self-administered home-treatment, encompassing transcranial direct current stimulation (tDCS) along with a video game based training of attentional control. The study is designed as a two-arm, double-blind, randomized and placebo-controlled multi-center trial (ClinicalTrials.gov: NCT04953208). At three study sites (Israel, Latvia, and Germany), 114 patients with a primary diagnosis of MDD undergo 6 weeks of intervention (30 × 30 min sessions). Patients assigned to the intervention group receive active tDCS (anode F3 and cathode F4; 2 mA intensity) and an action-like video game, while those assigned to the control group receive sham tDCS along with a control video game. An electrode-positioning algorithm is used to standardize tDCS electrode positioning. Participants perform their designated treatment at the clinical center (sessions 1–5) and continue treatment at home under remote supervision (sessions 6–30). The endpoints are feasibility (primary) and safety, treatment efficacy (secondary, i.e., change of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at week six from baseline, clinical response and remission, measures of social, occupational, and psychological functioning, quality of life, and cognitive control (tertiary). Demonstrating the feasibility, safety, and efficacy of this novel combined intervention could expand the range of available treatments for MDD to neuromodulation enhanced interventions providing cost-effective, easily accessible, and low-risk treatment options.ClinicalTrials.gov: NCT04953208.
- Open Access
- 1 January 2022
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 44 (6) , 1-8
Interventional psychiatry: the elephants in the room
- 1 January 2022
- Published by EDITORA SCIENTIFIC in Brazilian Journal of Psychiatry
- Vol. 44 (6) , 1-8
Open AccessInterventional psychiatry: the elephants in the room
- 20 November 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 267 (S2) , 109-112
Discovering the individual brain: brain stimulation in psychiatry
- 20 November 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 267 (S2) , 109-112
Discovering the individual brain: brain stimulation in psychiatry
- 28 February 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 267 (8) , 751-766
Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC)
Transcranial direct current stimulation (tDCS) has been proposed as novel treatment for major depressive disorder (MDD) based on clinical pilot studies as well as randomized controlled monocentric trials. The DepressionDC trial is a triple-blind (blinding of rater, operator and patient), randomized, placebo controlled multicenter trial investigating the efficacy and safety of prefrontal tDCS used as additive treatment in MDD patients who have not responded to selective serotonin reuptake inhibitors (SSRI). At 5 study sites, 152 patients with MDD receive a 6-weeks treatment with active tDCS (anode F3 and cathode F4, 2 mA intensity, 30 min/day) or sham tDCS add-on to a stable antidepressant medication with an SSRI. Follow-up visits are at 3 and 6 months after the last tDCS session. The primary outcome measure is the change of the Montgomery-Asberg Depression Rating Scale (MADRS) scores at week 6 post-randomisation compared to baseline. Secondary endpoints also cover other psychopathological domains, and a comprehensive safety assessment includes measures of cognition. Patients undergo optional investigations comprising genetic testing and functional magnetic resonance imaging (fMRI) of structural and functional connectivity. The study uses also an advanced tDCS technology including standard electrode positioning and recording of technical parameters (current, impedance, voltage) in every tDCS session. Aside reporting the study protocol here, we present a novel approach for monitoring technical parameters of tDCS which will allow quality control of stimulation and further analysis of the interaction between technical parameters and clinical outcome. The DepressionDC trial will hopefully answer the important clinical question whether prefrontal tDCS is a safe and effective antidepressant intervention in patients who have not sufficiently responded to SSRIs. Trial registry: ClinicalTrials.gov Identifier NCT0253016.
- 28 February 2017
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 267 (8) , 751-766
Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC)
Transcranial direct current stimulation (tDCS) has been proposed as novel treatment for major depressive disorder (MDD) based on clinical pilot studies as well as randomized controlled monocentric trials. The DepressionDC trial is a triple-blind (blinding of rater, operator and patient), randomized, placebo controlled multicenter trial investigating the efficacy and safety of prefrontal tDCS used as additive treatment in MDD patients who have not responded to selective serotonin reuptake inhibitors (SSRI). At 5 study sites, 152 patients with MDD receive a 6-weeks treatment with active tDCS (anode F3 and cathode F4, 2 mA intensity, 30 min/day) or sham tDCS add-on to a stable antidepressant medication with an SSRI. Follow-up visits are at 3 and 6 months after the last tDCS session. The primary outcome measure is the change of the Montgomery-Asberg Depression Rating Scale (MADRS) scores at week 6 post-randomisation compared to baseline. Secondary endpoints also cover other psychopathological domains, and a comprehensive safety assessment includes measures of cognition. Patients undergo optional investigations comprising genetic testing and functional magnetic resonance imaging (fMRI) of structural and functional connectivity. The study uses also an advanced tDCS technology including standard electrode positioning and recording of technical parameters (current, impedance, voltage) in every tDCS session. Aside reporting the study protocol here, we present a novel approach for monitoring technical parameters of tDCS which will allow quality control of stimulation and further analysis of the interaction between technical parameters and clinical outcome. The DepressionDC trial will hopefully answer the important clinical question whether prefrontal tDCS is a safe and effective antidepressant intervention in patients who have not sufficiently responded to SSRIs. Trial registry: ClinicalTrials.gov Identifier NCT0253016.
- 1 July 2016
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 13 (03) , 145-151
Brain stimulation methods for patients with schizophrenia – new therapies on the horizon?
Summary: Background: Non-invasive brain stimulation (NIBS) techniques offer new promising treatment options in schizophrenia. However, the evidence from meta-analyses and randomized clinical studies is limited. Results: For repetitive transcranial magnetic stimulation (rTMS) the clinical efficacy is highest for the 1-Hz rTMS over the left temporal cortex to improve auditory hallucinations, nevertheless there are studies showing no benefit. For negative symptoms rTMS could be offered keeping in mind the good tolerability. Transcranial direct current stimulation (tDCS) has a good risk-benefit ratio, but the evidence for schizophrenia symptoms is still derived from small sample studies. Electroconvulsive therapy (ECT) is the treatment option with the highest clinical efficacy for treatment-resistant schizophrenia, catatonia or other defined treatment circumstances, but has more adverse side effects. More research is needed to understand which stimulation technique could be recommended for a certain patient.
- 1 July 2016
- Published by Georg Thieme Verlag KG in Die Psychiatrie
- Vol. 13 (03) , 145-151
Brain stimulation methods for patients with schizophrenia – new therapies on the horizon?
Summary: Background: Non-invasive brain stimulation (NIBS) techniques offer new promising treatment options in schizophrenia. However, the evidence from meta-analyses and randomized clinical studies is limited. Results: For repetitive transcranial magnetic stimulation (rTMS) the clinical efficacy is highest for the 1-Hz rTMS over the left temporal cortex to improve auditory hallucinations, nevertheless there are studies showing no benefit. For negative symptoms rTMS could be offered keeping in mind the good tolerability. Transcranial direct current stimulation (tDCS) has a good risk-benefit ratio, but the evidence for schizophrenia symptoms is still derived from small sample studies. Electroconvulsive therapy (ECT) is the treatment option with the highest clinical efficacy for treatment-resistant schizophrenia, catatonia or other defined treatment circumstances, but has more adverse side effects. More research is needed to understand which stimulation technique could be recommended for a certain patient.
- 1 June 2016
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 35 (10) , 703-708
Standardisierte Anwendung der tDCS bei Depressionen
Hintergrund: Die transkranielle Gleichstromstimulation (tDCS) wird seit 10 Jahren zur Behandlung der Depression beforscht. Eine Reihe doppelblinder und offener Studien konnte überwiegend eine positive Wirkung der tDCS als Zusatzbehandlung zur medikamentösen Therapie nachweisen. Jedoch gibt es keine größeren Studien zur Anwendung der tDCS in naturalistischem Patientengut ohne studienbedingte Vorselektion durch Ein- und Ausschlusskriterien. Methodik: Das vorgestellte Positionspapier bewertet die Erkenntnisse einer Kombinationsbehandlung mit tDCS und Antidepressivum und empfiehlt eine standardisierte klinische Anwendung. Ein Fallbericht einer standardisierten Anwendung zeigte die Möglichkeit einer Anwendung in der klinischen Routine. Resultate: Die Anwendung von tDCS und begleitender antidepressiver Therapie ist in einer Reihe von Studien untersucht worden, wobei sich Stromstärke und Dauer der Anwendung in den letzten Jahren immer weiter erhöhten. In dem berichteten Fall kam es unter Medikation mit Citalopram 20 mg und intensivierter tDCS (20 Behandlungen zu je 30 min) zu einer raschen und nachhaltigen Verbesserung der depressiven Symptomatik, auch wenn eine Remission knapp nicht erreicht wurde. Schlussfolgerung: Die tDCS scheint bei Verwendung intensivierter Stimulationsprotokolle sicher anwendbar und könnte möglicherweise eine schnellere und nachhaltigere antidepressive Wirkung als eine medikamentöse Monotherapie bewirken. Daraus könnte sich eine weitreichende Bedeutung für die Behandlungsdauern der Erkrankung ergeben. Introduction: Transcranial direct current stimulation (tDCS) has been investigated for the treatment of depression over the last 10 years. Several double-blind and open label studies could show mostly positive effects of tDCS as an add-on to pharmacologic treatment. However, there is no larger study investigating the use of tDCS in a naturalistic patient sample without pre-study selection by inclusion and exclusion criteria. Methods and materials: The position paper presented here aims at evaluating current knowledge of a combined treatment with antidepressants and tDCS and suggests a standardized clinical application of tDCS in depressive disorders. A case report of standardized application shows the feasibility in clinical routine. Results: The application of tDCS as an add-on to antidepressant treatment has been investigated in several studies. Current strength and duration of application increased in the last years. We report a case of a patient who was treated with citalopram 20 mg and 20 tDCS sessions for 30 min each and who showed a quick and sustained improvement of depressive symptoms although remission was not fully obtained. Conclusions: tDCS might be applied safely even when using enhanced stimulation protocols and probably could exert a faster and more sustained improvement of depression the pharmacological monotherapy. This could have important implications for duration of treatment in depressive disorders.
- 1 June 2016
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 35 (10) , 703-708
Standardisierte Anwendung der tDCS bei Depressionen
Hintergrund: Die transkranielle Gleichstromstimulation (tDCS) wird seit 10 Jahren zur Behandlung der Depression beforscht. Eine Reihe doppelblinder und offener Studien konnte überwiegend eine positive Wirkung der tDCS als Zusatzbehandlung zur medikamentösen Therapie nachweisen. Jedoch gibt es keine größeren Studien zur Anwendung der tDCS in naturalistischem Patientengut ohne studienbedingte Vorselektion durch Ein- und Ausschlusskriterien. Methodik: Das vorgestellte Positionspapier bewertet die Erkenntnisse einer Kombinationsbehandlung mit tDCS und Antidepressivum und empfiehlt eine standardisierte klinische Anwendung. Ein Fallbericht einer standardisierten Anwendung zeigte die Möglichkeit einer Anwendung in der klinischen Routine. Resultate: Die Anwendung von tDCS und begleitender antidepressiver Therapie ist in einer Reihe von Studien untersucht worden, wobei sich Stromstärke und Dauer der Anwendung in den letzten Jahren immer weiter erhöhten. In dem berichteten Fall kam es unter Medikation mit Citalopram 20 mg und intensivierter tDCS (20 Behandlungen zu je 30 min) zu einer raschen und nachhaltigen Verbesserung der depressiven Symptomatik, auch wenn eine Remission knapp nicht erreicht wurde. Schlussfolgerung: Die tDCS scheint bei Verwendung intensivierter Stimulationsprotokolle sicher anwendbar und könnte möglicherweise eine schnellere und nachhaltigere antidepressive Wirkung als eine medikamentöse Monotherapie bewirken. Daraus könnte sich eine weitreichende Bedeutung für die Behandlungsdauern der Erkrankung ergeben. Introduction: Transcranial direct current stimulation (tDCS) has been investigated for the treatment of depression over the last 10 years. Several double-blind and open label studies could show mostly positive effects of tDCS as an add-on to pharmacologic treatment. However, there is no larger study investigating the use of tDCS in a naturalistic patient sample without pre-study selection by inclusion and exclusion criteria. Methods and materials: The position paper presented here aims at evaluating current knowledge of a combined treatment with antidepressants and tDCS and suggests a standardized clinical application of tDCS in depressive disorders. A case report of standardized application shows the feasibility in clinical routine. Results: The application of tDCS as an add-on to antidepressant treatment has been investigated in several studies. Current strength and duration of application increased in the last years. We report a case of a patient who was treated with citalopram 20 mg and 20 tDCS sessions for 30 min each and who showed a quick and sustained improvement of depressive symptoms although remission was not fully obtained. Conclusions: tDCS might be applied safely even when using enhanced stimulation protocols and probably could exert a faster and more sustained improvement of depression the pharmacological monotherapy. This could have important implications for duration of treatment in depressive disorders.
- 1 January 2016
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 33 (1) , 18-36
European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe
Purpose: Patients with chronic depression (CD) by definition respond less well to standard forms of psychotherapy and are more likely to be high utilizers of psychiatric resources. Therefore, the aim of this guidance paper is to provide a comprehensive overview of current psychotherapy for CD. The evidence of efficacy is critically reviewed and recommendations for clinical applications and research are given.Methods: We performed a systematic literature search to identify studies on psychotherapy in CD, evaluated the retrieved documents and developed evidence tables and recommendations through a consensus process among experts and stakeholders.Results: We developed 5 recommendations which may help providers to select psychotherapeutic treatment options for this patient group. The EPA considers both psychotherapy and pharmacotherapy to be effective in CD and recommends both approaches. The best effect is achieved by combined treatment with psychotherapy and pharmacotherapy, which should therefore be the treatment of choice. The EPA recommends psychotherapy with an interpersonal focus (e.g. the Cognitive Behavioural Analysis System of Psychotherapy [CBASP]) for the treatment of CD and a personalized approach based on the patient's preferences.Discussion: The DSM-5 nomenclature of persistent depressive disorder (PDD), which includes CD subtypes, has been an important step towards a more differentiated treatment and understanding of these complex affective disorders. Apart from dysthymia, ICD-10 still does not provide a separate entity for a chronic course of depression. The differences between patients with acute episodic depression and those with CD need to be considered in the planning of treatment. Specific psychotherapeutic treatment options are recommended for patients with CD.Conclusion: Patients with chronic forms of depression should be offered tailored psychotherapeutic treatments that address their specific needs and deficits. Combination treatment with psychotherapy and pharmacotherapy is the first-line treatment recommended for CD. More research is needed to develop more effective treatments for CD, especially in the longer term, and to identify which patients benefit from which treatment algorithm.
- 1 January 2016
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 33 (1) , 18-36
European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe
Purpose: Patients with chronic depression (CD) by definition respond less well to standard forms of psychotherapy and are more likely to be high utilizers of psychiatric resources. Therefore, the aim of this guidance paper is to provide a comprehensive overview of current psychotherapy for CD. The evidence of efficacy is critically reviewed and recommendations for clinical applications and research are given.Methods: We performed a systematic literature search to identify studies on psychotherapy in CD, evaluated the retrieved documents and developed evidence tables and recommendations through a consensus process among experts and stakeholders.Results: We developed 5 recommendations which may help providers to select psychotherapeutic treatment options for this patient group. The EPA considers both psychotherapy and pharmacotherapy to be effective in CD and recommends both approaches. The best effect is achieved by combined treatment with psychotherapy and pharmacotherapy, which should therefore be the treatment of choice. The EPA recommends psychotherapy with an interpersonal focus (e.g. the Cognitive Behavioural Analysis System of Psychotherapy [CBASP]) for the treatment of CD and a personalized approach based on the patient's preferences.Discussion: The DSM-5 nomenclature of persistent depressive disorder (PDD), which includes CD subtypes, has been an important step towards a more differentiated treatment and understanding of these complex affective disorders. Apart from dysthymia, ICD-10 still does not provide a separate entity for a chronic course of depression. The differences between patients with acute episodic depression and those with CD need to be considered in the planning of treatment. Specific psychotherapeutic treatment options are recommended for patients with CD.Conclusion: Patients with chronic forms of depression should be offered tailored psychotherapeutic treatments that address their specific needs and deficits. Combination treatment with psychotherapy and pharmacotherapy is the first-line treatment recommended for CD. More research is needed to develop more effective treatments for CD, especially in the longer term, and to identify which patients benefit from which treatment algorithm.
- 1 August 2015
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 83 (08) , e11-e13
Transcranial Direct Current Stimulation (tDCS) in a Patient with PRES and Bipolar Depression
Transcranial direct current stimulation (tDCS) is a non-invasive tool for brain stimulation and has proven efficacy in depressive disorders. Here, we report the case of a patient with recurrent bipolar depressive disorder and neurologic complications due to posterior reversible encephalopathy syndrome (PRES) due to parathyroid adenoma. During a long-term hospital stay, multiple drug regimens did not resolve depressive symptoms. Finally, an add-on therapy with tDCS brought improvement of symptoms. This case highlights the feasibility of tDCS in treatment-resistant depression and concomitant neurologic disorder. Transkranielle Gleichstromstimulation (tDCS) ist ein nicht-invasives Hirnstimulationsverfahren, das zur Behandlung der Depression eingesetzt wird. Wir berichten über eine Patientin mit rezidivierenden depressiven Episoden im Rahmen einer bipolar-affektiven Störung und neurologischer Komplikationen bei posteriorem reversiblem Enzephalopathie-Syndrom (PRES) aufgrund eines Nebenschilddrüsenadenoms. Während eines längerfristigen Krankenhausaufenthalts wurden verschiedene psychopharmakologische Therapieversuche erfolglos durchgeführt. Schließlich wurde eine Gleichstromstimulation zusätzlich zur Medikation angewendet und brachte eine Verbesserung der Symptome. Dieser Fall zeigt die problemlose Anwendbarkeit der tDCS bei therapieresistenter Depression und begleitender neurologischer Erkrankung.
- 1 August 2015
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 83 (08) , e11-e13
Transcranial Direct Current Stimulation (tDCS) in a Patient with PRES and Bipolar Depression
Transcranial direct current stimulation (tDCS) is a non-invasive tool for brain stimulation and has proven efficacy in depressive disorders. Here, we report the case of a patient with recurrent bipolar depressive disorder and neurologic complications due to posterior reversible encephalopathy syndrome (PRES) due to parathyroid adenoma. During a long-term hospital stay, multiple drug regimens did not resolve depressive symptoms. Finally, an add-on therapy with tDCS brought improvement of symptoms. This case highlights the feasibility of tDCS in treatment-resistant depression and concomitant neurologic disorder. Transkranielle Gleichstromstimulation (tDCS) ist ein nicht-invasives Hirnstimulationsverfahren, das zur Behandlung der Depression eingesetzt wird. Wir berichten über eine Patientin mit rezidivierenden depressiven Episoden im Rahmen einer bipolar-affektiven Störung und neurologischer Komplikationen bei posteriorem reversiblem Enzephalopathie-Syndrom (PRES) aufgrund eines Nebenschilddrüsenadenoms. Während eines längerfristigen Krankenhausaufenthalts wurden verschiedene psychopharmakologische Therapieversuche erfolglos durchgeführt. Schließlich wurde eine Gleichstromstimulation zusätzlich zur Medikation angewendet und brachte eine Verbesserung der Symptome. Dieser Fall zeigt die problemlose Anwendbarkeit der tDCS bei therapieresistenter Depression und begleitender neurologischer Erkrankung.
- 1 January 2015
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 60, 170-177
Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression
- 1 January 2015
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 60, 170-177
Effects of social exclusion on emotions and oxytocin and cortisol levels in patients with chronic depression
- 1 January 2015
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 34 (12) , 987-993
Chronischer Tinnitus
Zum Einsatz der repetitiven transkraniellen Magnetstimulation (rTMS) in der Behandlung des chronischen Tinnitus liegen 20 randomisierte placebokontrollierte Studien vor. In der Mehrzahl der Studien erfolgte die Behandlung mit niederfrequenter (1 Hz) rTMS über dem temporalen oder temporoparietalen Kortex. Die Spulenlokalisation erfolgte in den meisten Studien entweder linksseitig oder kontralateral zur Tinnituslateralität. Bei der Betrachtung ergibt sich kein eindeutiges Bild. Die Unterschiede in den Ergebnissen der einzelnen Studien könnten bedingt sein durch die Heterogenität der Stimulationsprotokollen und der Studiendesigns. Die Mehrzahl der Studien zeigte einen Nutzen der aktiven Stimulation im Vergleich zur Sham-Stimulation. Die Effektstärke war jedoch klein, der Effekt war in einzelnen (auch methodisch hochwertigen) Studien nicht nachweisbar und die Dauer des Behandlungseffektes bleibt ungewiss. Mehrere Studien legen nahe, dass die Behandlungseffekte durch die zusätzliche hochfrequente rTMS des linken frontalen Kortex verstärkt werden können. Aufgrund der nicht ganz eindeutigen Studienlage kann für den Einsatz der rTMS in der Behandlung des chronischen Tinnitus lediglich die Empfehlung mit Level C (mögliche Effekte wiederholter niederfrequenter rTMS-Sitzungen des temporalen/temporoparietalen Kortex) ausgesprochen werden. Twenty randomized and placebo-controlled clinical trials have been performed for investigating the treatment of chronic tinnitus with repetitive transcranial magnetic stimulation (rTMS). In most cases rTMS was delivered following a low-frequency paradigm (1 Hz) targeting the left or contralateral (regarding the tinnitus percept) temporal or temporoparietal cortex. No consistent conclusion can be drawn based on these data so far. Differences in the outcome of the single studies might be attributed to heterogeneity in stimulation protocols and study designs. The majority of the presented studies demonstrated advantages of active rTMS stimulation compared to sham-stimulation. However, treatment effects were only moderate, not detectable in some (even methodologically sophisticated) studies, and the duration of treatment effects is uncertain. Some studies suggest that treatment effects might be enhanced by additional high-frequency rTMS of left frontal cortical areas. Due to the inconsistent character of current study results, only a level-C-recommendation (possible effects) can be obtained regarding serial application of low-frequency rTMS targeting the temporal/temporoparietal cortex. * Dieses Manuskript wurde als Positionspapier der Deutschen Gesellschaft für Hirnstimulation in der Psychiatrie (DGHP) erarbeitet
- 1 January 2015
- Published by Georg Thieme Verlag KG in Nervenheilkunde
- Vol. 34 (12) , 987-993
Chronischer Tinnitus
Zum Einsatz der repetitiven transkraniellen Magnetstimulation (rTMS) in der Behandlung des chronischen Tinnitus liegen 20 randomisierte placebokontrollierte Studien vor. In der Mehrzahl der Studien erfolgte die Behandlung mit niederfrequenter (1 Hz) rTMS über dem temporalen oder temporoparietalen Kortex. Die Spulenlokalisation erfolgte in den meisten Studien entweder linksseitig oder kontralateral zur Tinnituslateralität. Bei der Betrachtung ergibt sich kein eindeutiges Bild. Die Unterschiede in den Ergebnissen der einzelnen Studien könnten bedingt sein durch die Heterogenität der Stimulationsprotokollen und der Studiendesigns. Die Mehrzahl der Studien zeigte einen Nutzen der aktiven Stimulation im Vergleich zur Sham-Stimulation. Die Effektstärke war jedoch klein, der Effekt war in einzelnen (auch methodisch hochwertigen) Studien nicht nachweisbar und die Dauer des Behandlungseffektes bleibt ungewiss. Mehrere Studien legen nahe, dass die Behandlungseffekte durch die zusätzliche hochfrequente rTMS des linken frontalen Kortex verstärkt werden können. Aufgrund der nicht ganz eindeutigen Studienlage kann für den Einsatz der rTMS in der Behandlung des chronischen Tinnitus lediglich die Empfehlung mit Level C (mögliche Effekte wiederholter niederfrequenter rTMS-Sitzungen des temporalen/temporoparietalen Kortex) ausgesprochen werden. Twenty randomized and placebo-controlled clinical trials have been performed for investigating the treatment of chronic tinnitus with repetitive transcranial magnetic stimulation (rTMS). In most cases rTMS was delivered following a low-frequency paradigm (1 Hz) targeting the left or contralateral (regarding the tinnitus percept) temporal or temporoparietal cortex. No consistent conclusion can be drawn based on these data so far. Differences in the outcome of the single studies might be attributed to heterogeneity in stimulation protocols and study designs. The majority of the presented studies demonstrated advantages of active rTMS stimulation compared to sham-stimulation. However, treatment effects were only moderate, not detectable in some (even methodologically sophisticated) studies, and the duration of treatment effects is uncertain. Some studies suggest that treatment effects might be enhanced by additional high-frequency rTMS of left frontal cortical areas. Due to the inconsistent character of current study results, only a level-C-recommendation (possible effects) can be obtained regarding serial application of low-frequency rTMS targeting the temporal/temporoparietal cortex. * Dieses Manuskript wurde als Positionspapier der Deutschen Gesellschaft für Hirnstimulation in der Psychiatrie (DGHP) erarbeitet